Castlebiosciences.com
IDgenetix How It Works Castle Biosciences
WebThe one-size-fits-all approach to mental health treatment works for no one. IDgenetix is a comprehensive pharmacogenomics (PGx) test that provides personalized medication profiles, tailored to a patient’s unique DNA. The test accounts for more factors that can influence a patient’s response to medication than any other PGx test.
Actived: 8 days ago
URL: https://castlebiosciences.com/tests/pharmacogenomic-pgx/idgenetix/how-it-works
Castle Biosciences Innovative Molecular Diagnostics
WebClinical focus areas. Our broad portfolio of innovative tests focuses on answering critical clinical questions. From individualized risk of melanoma metastasis to customized medication profiles for mental health conditions, our tests are designed to deliver personalized information that better informs care decisions. Patient Information.
IDgenetix Castle Biosciences
WebPharmacogenomics, also known as PGx, is the study of how a person's genes affect how he or she responds to medications. The goal of PGx is to help doctors personalize a patient’s treatment - selecting the drugs and doses best suited for each individual patient. IDgenetix is an advanced precision medicine solution that sets a new standard for
Castle Biosciences Inc.
WebIDgenetix is a clinically validated pharmacogenomic (PGx) test that incorporates drug-gene interactions, drug-drug interactions and lifestyle factors to guide medication management for patients’ neuropsychiatric conditions, such as depression and anxiety Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through …
Castle Biosciences to Present at the 22nd Annual Needham Virtual
WebCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 22nd Annual Needham Virtual Healthcare …
Pharmacogenomics Castle Biosciences
WebPharmacogenomic testing (PGx) is the analysis of an individual's genetic makeup to determine how their genes may affect their response to medications, allowing for personalized and optimized drug therapy based on genetic variations. It helps predict drug efficacy, dosage adjustments, and potential adverse reactions, improving treatment …
About Us Castle Biosciences
WebOur science is complex. From the beginning, Castle Biosciences was driven by a desire to help patients receive the best care possible. Our founder believed that the traditional methods to determine cancer patients' prognoses could be improved by harnessing the biology of their tumors. Through this belief, Castle was born.
Castle Biosciences Announces Updates to its Board of Directors
WebCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle’s 2024 Annual Meeting of Stockholders, expected to be held in May 2024. The …
IDgenetix Practice Integration Castle Biosciences
WebIDgenetix is a CLIA certified, CAP-accredited and NY state approved Molecular Pharmacogenomics Clinical Laboratory. IDgenetix PGx Testing is offered in all 50 states. Match patients to the right medication and help improve response and remission rates with comprehensive genetic analysis.
Castle Biosciences to Present at the 23rd Annual Needham Virtual
WebCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. …
Castle Biosciences Completes Acquisition of AltheaDx
WebFRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has completed its acquisition of AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field …
Technology Castle Biosciences
WebLeveraging advanced technologies for innovative tests. We believe disease management and treatment decisions can be best be informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative assays that aid healthcare providers in improving patient outcomes. Our tests characterize an individual
TissueCypher Scientific Evidence Castle Biosciences
WebTissue from 154 patents from the SURF trial was evaluated by TissueCypher as well as 30 expert and general pathologists. Care plans were evaluated with and without guidance from TissueCypher and results indicated that TissueCypher may be used to standardize management of BE patients to improve health outcomes.
Castle Biosciences to Host Second Annual Castle Cares Charity Walk
WebCastle employees to raise funds and awareness for five partner organizations in support of patients impacted by skin cancer, esophageal cancer, mental health conditions and uveal melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, announced that it will host its second …
Castle Biosciences Inc.
WebThis marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the “Best Overall Mental Health …
Cutaneous Melanoma Diagnosis & Evaluation Castle Biosciences
WebThere is no evidence the cancer has spread to the lymph nodes or distant sites (metastasis). There are two subgroups of Stage I: IA and IB. The subgroup assignment depends on the thickness of the tumor and if ulceration is seen under a microscope. Stage II. Stage II melanoma is defined by tumor thickness and ulceration.
Cutaneous Squamous Cell Carcinoma Castle Biosciences
WebThe sample will be sent to a laboratory for a pathologist to review, who will confirm or rule out a diagnosis of skin cancer. Once an SCC diagnosis is confirmed, your doctor will assess your SCC based on a number of factors, such as size, location, depth, etc., and may order a DecisionDx-SCC Test to evaluate the risk of your SCC spreading.
Top Categories
Popular Searched
› Public health ontario laboratory report
› Health insurance 26th birthday
› Barnes healthcare services store
› Mental health advocacy statistics
› Olmsted county mental health
› Texas health education programs
› Healthy and safety procedures iso standard
› How to become a healthcare surveyor
› Home health care self survey
Recently Searched
› Frank health insurance member area register
› Boost health insurance agency llc
› Texas education agency health education
› Ontario health virtual visit verification
› Lane center for academic health
› Center for healthy living medicare plans
› Pnw natural health nature boost
› Phcs insurance health shield basic